178 related articles for article (PubMed ID: 25639366)
1. Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
J Pharm Sci; 2015 Sep; 104(9):3039-48. PubMed ID: 25639366
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin.
Futatsugi A; Toshimoto K; Yoshikado T; Sugiyama Y; Kato Y
Drug Metab Dispos; 2018 May; 46(5):749-757. PubMed ID: 29440178
[TBL] [Abstract][Full Text] [Related]
3. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
5. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
6. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
[TBL] [Abstract][Full Text] [Related]
7. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Humphreys JE; Lou Y; Lee EJ
J Pharm Sci; 2010 Feb; 99(2):1046-62. PubMed ID: 19569219
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
Karibe T; Hagihara-Nakagomi R; Abe K; Imaoka T; Mikkaichi T; Yasuda S; Hirouchi M; Watanabe N; Okudaira N; Izumi T
Pharm Res; 2015 May; 32(5):1634-47. PubMed ID: 25380981
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
10. BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications.
Hira D; Terada T
Biochem Pharmacol; 2018 Jan; 147():201-210. PubMed ID: 29031817
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
[TBL] [Abstract][Full Text] [Related]
12. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
13. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
14. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
15. Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans.
Kim KA; Cha YJ; Lee HM; Joo HJ; Park JY
Clin Chim Acta; 2015 Jan; 438():7-11. PubMed ID: 25124867
[TBL] [Abstract][Full Text] [Related]
16. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2).
Ieiri I
Drug Metab Pharmacokinet; 2012; 27(1):85-105. PubMed ID: 22123128
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
18. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
19. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
Kashihara Y; Ieiri I; Yoshikado T; Maeda K; Fukae M; Kimura M; Hirota T; Matsuki S; Irie S; Izumi N; Kusuhara H; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2688-2694. PubMed ID: 28322941
[TBL] [Abstract][Full Text] [Related]
20. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
